

FP CARMIGNAC EUROPEAN LEADERS: LETTER FROM THE FUND MANAGER

16/02/2024 | MARK DENHAM

+6.70%

Performance of the Fund in the quarter vs +7.57% for its reference indicator¹ (A GBP Acc Share class).

+13.90%

Performance of the Fund in 2023 vs +14.83% for its reference indicator.

+11.58%

Annualised performance of the Fund since inception² versus +8.32% for the Reference indicator.

*During the fourth quarter of 2023, the return of **FP Carmignac European Leaders** (A GBP Acc share class) was a positive return of +6.7%, providing a return below the reference indicator which rose 7.57%. This meant for the full year, the fund rose +13.9% compared to the reference indicator which rose +14.83%.*

MARKET ENVIRONMENT DURING THE PERIOD

The year started strongly, continuing the momentum that had started in the previous quarter. Recession worries faded due to fiscal support for consumers, falling gas prices in Europe, as well as a rapid Chinese reopening. Just when European markets had come to grips with the multiple central bank rate hikes, attention shifted to commercial banks as they raised investor concerns on the back of US and Swiss bank failures. In the meantime, energy prices and overall inflation had started to subside and China's post-Covid lockdown release had re-started global supply chains helping further ease inflation concerns. As a result, the widely anticipated recession had been pushed back and the macroeconomic outlook had become less gloomy.

Following the strong performance of European equities in the first half of the year, markets fell back in the third quarter. While the second quarter earnings reporting season had been relatively uneventful, and consistent with full year expectations of little profits growth overall, worldwide pressure on stock prices came once again from ever-rising bond yields. European markets rebounded in the last quarter and finished the year by rising c7% in the quarter to finish the year up a respectable 16%. The catalyst for this was the prospect of an easing of monetary policy in 2024. The European Central Bank (ECB) announced in late Q3 that they had completed their interest rate hikes. Following this announcement, we received a series of positive inflation reports, culminating in a Consumer Price Index (CPI) reading of approximately 2.4% in November, compared to 10% in November of the previous year. Similar trends were observed in the United States. The US Federal Reserve (Fed) subsequently confirmed interest rates will likely be cut in 2024, thus raising the prospect of a so-called "soft landing" with inflation under control, falling interest rates and no recession. It is worth noting, however, that the ECB chose to maintain a more orthodox stance than its American counterpart, indicating that possible rate cuts were not yet on the agenda.

HOW DID WE FARE IN THIS CONTEXT ?

During the year, the Fund recorded a positive absolute performance, though below its reference indicator. In the first months of the year, the sectoral mix was unfavourable for our strategy as we have little exposure to banks, retail and autos, however the volatility in March allowed us to catch up and finish the period in line with our reference indicator, helped by the fact we had no bank exposure.

During the first quarter, Technology names delivered a strong contribution. Our second best contributor during the year, SAP, rose 47% thanks to a strong first quarter, where the company delivered impressive full year results, demonstrating ongoing strong momentum in cloud business with strong sales growth underlining the fact that the transition of customers from license-based products to more valuable cloud-based ones is consistent. During the second quarter, Healthcare overall was not a particularly strong sector in the period, but our names did particularly well. Zealand Pharma, a drug company exposed to obesity, rose 14% ahead of strong clinical data for one of their candidates at an industry conference, while our smallest healthcare name, the biotech Merus, rose a stunning 40%.

In the third quarter, some stock specific events disappointed and weighed on returns. Indeed, Orsted, the wind farm developer, took additional write downs on unprofitable projects in the US due to cost overruns and rising interest costs, among other things. We sold out of our remaining holding after the announcement when the stock fell significantly. On the positive side, our largest position, Novo Nordisk, the drug company at the forefront of the new class of drugs, GLP-1 agonists, to treat diabetes and obesity, saw its shares rise a further 8% in the quarter and therefore 50% for the year. The company delivered better than expected results and upgraded their full year expectations, owing to sustained demand for their diabetes product. Novo is one of the few names that was a strong performer in 2022 and 2023, yet we maintain it as our largest holding. We expect ongoing penetration of GLP-1 drugs in treatment of diabetes and increased supply of drugs for obesity to satisfy demand, to drive higher growth than the market anticipates in the coming quarters and years.

After a temporary headwind for our Fund in the third quarter, the last months of the year registered solid performance. Schneider Electric, one of our larger holdings, rose 17%, helped by continued strong growth delivered in their 3rd quarter results, as well as confirming strong demand for electrical infrastructure in several end markets such as data centres, EV infrastructure and electricity grid upgrades.

OUTLOOK

The Fund continues to rely on bottom-up fundamental analysis and have used the strength to reduce cyclical exposure after the rally in the last quarter. If interest rates were to further decrease, it would undoubtedly provide support for our portfolio holdings. However, we remain cautious of the potential impact of weaker corporate and economic data, and the risk to earnings faced by cyclical businesses notwithstanding their quality. Looking into 2024, our perspective remains that there is a disproportionate downside risk for earnings per share and gross domestic product in this context and that bad news will start to be seen as detrimental. The potential for greater visibility in the market is expected to yield favourable outcomes, which is why we are committed to maintaining our position. Consequently, we aim to mitigate any potential risks associated with net cyclical, beta, momentum, and illiquidity. Having added numerous names to the fund in 2022, when we picked up many high-quality names sold off in the volatility caused by rising rates, we have made few large changes to the portfolio in 2023. We have an investment horizon of 5 years, and we stick to our process of focusing on profitable companies with high returns on capital, reinvesting for growth. We believe these companies will continue to deliver the best long-term returns for investors.

¹ MSCI Europe Ex UK Net Total Return USD.

² The Fund was launched on 15 May 2019.

Source: Carmignac, Bloomberg as of 29 December 2023.

SFDR - Fund Classification :

Article -



Recommended
minimum
investment horizon



MAIN RISKS OF THE FUND

EQUITY: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization. **CURRENCY:** Currency risk is linked to exposure to a currency other than the Fund's valuation currency, either through direct investment or the use of forward financial instruments. **DISCRETIONARY MANAGEMENT:** Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.

The Fund presents a risk of loss of capital.

* Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time.

FEES

Maximum subscription fees paid to distributors : 0,00%

Redemption Fees : 0,00%

Conversion Fee : •

Ongoing Charges : 0.89%

Management Fees : 0,81% EXT

Performance Fees : •

ANNUALISED PERFORMANCE (ISIN: GB00BJHPHZ49)

Calendar Year Performance (as %)	2019	2020	2021	2022	2023
FP Carmignac European Leaders	+18.2 %	+27.1 %	+13.9 %	-14.8 %	+13.9 %
Indicateur de référence	+8.8 %	+7.5 %	+16.7 %	-7.6 %	+14.8 %

Annualised Performance	1 Year	3 Years	Since launch
FP Carmignac European Leaders	+12.6 %	+4.6 %	+12.3 %
Indicateur de référence	+8.0 %	+6.6 %	+8.7 %

Source: Carmignac at 30 Apr 2024.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.

The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds' prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com, or upon request to the Management Company. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

- **In France, Luxembourg, Sweden:** The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds' prospectus, KIDs, NAV and annual reports are available at www.carmignac.com, or upon request to the Management Company.
- **In the United Kingdom:** the Funds' respective prospectuses, KIIDs and annual reports are available at www.carmignac.co.uk, or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the "Company") is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the "ACD") of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.
- **In Switzerland:** the prospectus, KIDs and annual report are available at www.carmignac.ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime.

Investors have access to a summary of their rights in English on the following links: [UK](#) ; [Switzerland](#) ; [France](#) ; [Luxembourg](#) ; [Sweden](#).